Danielle Ternyila

Articles

Finn Sheds Light on Single-Agent Pembrolizumab Data in Advanced HCC

July 23rd 2019

Richard S. Finn, MD, discusses results from the KEYNOTE-240 trial and explained how they are still clinically meaningful for patients with hepatocellular carcinoma.

ctDNA Monitoring Carries Clinical Validity in Advanced BRAF-Mutant Melanoma

July 23rd 2019

David Polsky, MD, PhD, discusses findings from an analysis in patients with BRAF-mutant, unresectable, metastatic melanoma, as well as the next steps for validating these findings and potentially using circulating tumor DNA to help inform treatment decisions.

Rituximab Regimen Elicits High ORR in Relapsed MCL

July 17th 2019

Rory McCulloch, MD, discusses the results of a retrospective analysis looking at rituximab, bendamustine, and cytarabine in patients with mantle cell lymphoma who have relapsed on a BTK inhibitor.

Expert Expands on Implications of Molecular Targets in Myelofibrosis

May 29th 2019

Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with myelofibrosis to determine the value of mutational profiling in predicting outcomes after transplant.

Significance of Genetic Testing Continues to Increase in Breast Cancer

May 29th 2019

Banu Arun, MD, discusses how the role of genetic testing is evolving in breast cancer with the development of new targeted agents.

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases

May 24th 2019

Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose of osimertinib in patients with EGFR-mutant non–small cell lung cancer with leptomeningeal metastases.

Expert Explains Expanding Post-Ibrutinib Options in CLL

May 24th 2019

Jacqueline C. Barrientos, MD, MS, highlights emerging agents in the post-ibrutinib landscape and overall next steps for advancing the field of CLL.

Expert Shares Advantages, Challenges With Liquid Biopsies in Cancer Care

May 23rd 2019

Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.

Durvalumab Being Explored in Real-World Setting of Locally Advanced Stage III NSCLC

May 21st 2019

Nicolas Girad, MD, discusses the importance of evaluating durvalumab in a real-world setting, other questions that remain unanswered in this area, and the role of immunotherapy in patients with non–small cell lung cancer.

Frontline Afatinib Shows Promise in EGFR+ NSCLC

May 21st 2019

Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.

Role of Liquid Biopsies Still Needs Refining in Breast Cancer

April 25th 2019

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Quizartinib Poised to Expand FLT3 Inhibition Options in AML

April 16th 2019

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Bladder Cancer Guidelines Showcase Advent of Immunotherapy

March 24th 2019

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.

NCCN Guidelines Update Increases Role of Genetic Testing in Prostate Cancer

March 23rd 2019

Emmanuel S. Antonarakis, MD, discusses the prevalence of mismatch repair and homologous recombination deficiency genes and how they may play a role in determining a patient’s treatment plan in addition to promising agents that have been introduced to the field in clinical trials.

Expert Addresses Therapeutic Updates for Breast Cancer Subtypes

March 22nd 2019

William J. Gradishar, MD, discusses the latest updates in HER2-negative advanced breast cancer and the role of molecular assays in this space.

Agents Emerging in Late Relapsed/Refractory Myeloma Space

March 3rd 2019

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Jabbour Highlights Ongoing Research, Current Treatment for ALL Subtypes

March 2nd 2019

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

Targeted Therapies Continue to Show Promise Against FLT3, IDH1/2 Mutations in AML

March 2nd 2019

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23rd 2019

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

Locke Covers AE Management Linked With CAR T-Cell Therapies

February 22nd 2019

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.